News & Events
Published On: 10/31/2018
TARGET PharmaSolutions Initiates a New Community, TARGET-HBV, to Advance the Understanding of Hepatitis B
CHAPEL HILL, NC – October 31, 2018 / PR NEWSWIRE / – TARGET PharmaSolutions, Inc., a company focused on real world evidence, is pleased to announce that it has started enrolling patients in TARGET-HBV.
TARGET-HBV is an observational study that will conduct a comprehensive review of patients with chronic hepatitis B virus (HBV) infection. TARGET-HBV plans to enroll up to 5,000 patients across a large network of academic and community sites in the United States to advance the understanding of hepatitis B.
Dr. Anna Lok, TARGET-HBV Scientific Advisor, explained “TARGET-HBV is timely given the renewed interest in finding a cure for hepatitis B. Chronic hepatitis B is characterized by fluctuations in virus replication and disease activity; thus, while guidelines exist, management of individual patients can be nuanced. Data on a large cohort of hepatitis B patients managed in the real-world will provide insights into the course of this disease and guide the use of future therapies.”
Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions, stated “We are very excited that we have started enrolling patients in our TARGET-HBV community. We have seen significant interest from investigative sites to participate in this important study, and we look forward to continuing to advance the understanding of this challenging disease.”
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
08/25/2022New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)
08/24/2022Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest Acquisition
08/23/2022Target RWE New Brand, Research, and Advanced Real World Evidence Analytics Showcased at International Conference on Pharmacoepidemiology (ICPE) 2022
07/20/2022Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis Population
06/24/2022Nonalcoholic Fatty Liver Disease (NAFLD) Research from Target RWE's Real-World Study Presented at International Liver Congress 2022